Gentilini P, Laffi G, La Villa G, Romanelli R G, Buzzelli G, Casini-Raggi V, Melani L, Mazzanti R, Riccardi D, Pinzani M, Zignego A L
Istituto di Medicina Interna, University of Florence, School of Medicine, Italy.
Am J Gastroenterol. 1997 Jan;92(1):66-72.
Chronic infection by hepatitis B virus (HBV) and hepatitis C virus (HCV) is now recognized as a major cause of liver cirrhosis. This study was aimed at evaluating the natural history of the disease in a large series of Italian patients with HBV- and HCV-related cirrhosis without portal hypertension at entry.
The clinical records of 405 patients (233 males, mean age 54 +/- 9 yr) with histologically proven cirrhosis (321 with HCV-related and 84 with HBV-related cirrhosis) and no clinical evidence of portal hypertension at entry were retrospectively examined to evaluate the occurrence of complications and the cumulative mortality rate during follow-up.
Patients had a mean follow-up of 8 +/- 3 yr. The cumulative survival rate was 99.1% at 5 yr, 76.8% at 10 yr, and 49.4% at 15 yr. The age-adjusted death rate was 3.14 and 2.84 times higher than in the general Italian population in men and women, respectively. Only the bilirubin level was an independent indicator of survival. Esophageal varices, ascites, jaundice, hemorrhage, hepatic encephalopathy, and hepatocellular carcinoma significantly reduced the survival rate (major complications), whereas thrombocytopenia, diabetes, and cholelithiasis did not affect survival (minor complications). The incidence of hepatocellular carcinoma was similar in patients with either HBV- or HCV-related disease and was quite frequent, especially in males.
This study demonstrates that the course of virus-induced liver cirrhosis is not influenced by the etiology of the disease and that the occurrence of complications significantly shortens life expectancy. The longer survival rate observed in this study is probably due to the fact that cirrhosis was here recognized by liver biopsy in the absence of clinical evidence of portal hypertension.
乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)的慢性感染目前被认为是肝硬化的主要病因。本研究旨在评估一大批初诊时无门静脉高压的意大利HBV和HCV相关肝硬化患者的疾病自然史。
回顾性检查405例患者(233例男性,平均年龄54±9岁)的临床记录,这些患者经组织学证实为肝硬化(321例为HCV相关肝硬化,84例为HBV相关肝硬化),初诊时无门静脉高压的临床证据,以评估随访期间并发症的发生情况和累积死亡率。
患者的平均随访时间为8±3年。5年时的累积生存率为99.1%,10年时为76.8%,15年时为49.4%。年龄调整后的死亡率在男性和女性中分别比意大利普通人群高3.14倍和2.84倍。只有胆红素水平是生存的独立指标。食管静脉曲张、腹水、黄疸、出血、肝性脑病和肝细胞癌显著降低了生存率(主要并发症),而血小板减少症、糖尿病和胆石症不影响生存(次要并发症)。HBV或HCV相关疾病患者的肝细胞癌发病率相似,且相当常见,尤其是在男性中。
本研究表明,病毒诱导的肝硬化病程不受疾病病因的影响,并发症的发生显著缩短预期寿命。本研究中观察到的较长生存率可能是由于在无门静脉高压临床证据的情况下通过肝活检确诊肝硬化。